Bio Bench specializes in the development of customized monoclonal antibodies and biologically active proteins, offering a comprehensive range of services tailored for drug discovery and diagnostic applications. Their capabilities include a 100-billion-clone human naive antibody library, which is designed for antibody drug discovery, and hybridoma technology for producing mouse and rat monoclonal antibodies. Bio Bench also employs phage display techniques, allowing for a wide selection of host animals and the generation of up to 500 clones, making it adaptable for various research and therapeutic applications. Their antibody engineering services encompass affinity maturation, humanization, and the creation of bi-specific antibodies, ensuring high specificity and efficacy in therapeutic contexts.

In addition to antibody development, Bio Bench provides customized cell line and protein expression services across a variety of host systems, including E. coli, yeast, and mammalian cells. They focus on optimizing expression levels and purification strategies, achieving up to 99.9% purity in their products. Their GMP-certified laboratory ensures that the production processes meet clinical trial standards. Bio Bench also offers integrated solutions for therapeutic drug discovery, from target analysis to candidate generation and CMO production, as well as assay kit development for various industries, demonstrating their commitment to advancing biopharmaceutical research and commercialization.

China

Bio Bench co. ltd (www.bio-bench.com, Belgium and China) is aCRO (Contract Research Organization) that develops functionalantibodiesand bio-active proteins for drug discovery, in-vitro diagnostickits and biologicalresearch.

Bio Bench

Company Details